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Abstract 
 
Despite substantial advances in the treatment of various cancers, many patients still receive 
anti-cancer therapies that hardly eradicate tumor cells but inflict considerable side effects. To provide 
the best treatment regimen for an individual patient, a major goal in molecular oncology is to identify 
predictive markers for a personalized therapeutic strategy. Regarding novel targeted anti-cancer 
therapies, there are usually good markers available. Unfortunately, however, targeted therapies alone 
often result in rather short remissions and little cytotoxic effect on the cancer cells. Therefore, 
classical chemotherapy with frequent long remissions, cures, and a clear effect on cancer cell 
eradication remains a corner stone in current anti-cancer therapy. Reliable biomarkers which predict 
the response of tumors to classical chemotherapy are rare, in contrast to the situation for targeted 
therapy. For the bulk of cytotoxic therapeutic agents, including DNA-damaging drugs, drugs targeting 
microtubules or antimetabolites, there are still no reliable biomarkers used in the clinic to predict 
tumor response. To make progress in this direction, meticulous studies of classical chemotherapeutic 
drug action and resistance mechanisms are required. For this purpose, novel functional screening 
technologies have emerged as successful technologies to study chemotherapeutic drug response in a 
variety of models. They allow a systematic analysis of genetic contributions to a drug-responsive or –
sensitive phenotype and facilitate a better understanding of the mode of action of these drugs. These 
functional genomic approaches are not only useful for the development of novel targeted anti-cancer 
drugs but may also guide the use of classical chemotherapeutic drugs by deciphering novel 
mechanisms influencing a tumor’s drug response. Moreover, due to the advances of 3D organoid 
cultures from patient tumors and in vivo screens in mice, these genetic screens can be applied using 
conditions that are more representative of the clinical setting. Patient-derived 3D organoid lines 
furthermore allow the characterization of the “essentialome”, the specific set of genes required for 
survival of these cells, of an individual tumor, which could be monitored over the course of treatment 
and help understanding how drug resistance evolves in clinical tumors. Thus, we expect that these 
functional screens will enable the discovery of novel cancer-specific vulnerabilities, and through 
clinical validation, move the field of predictive biomarkers forward. This review focuses on novel 
advanced techniques to decipher the interplay between genetic alterations and drug response. 
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1. Introduction 
Anti-cancer drug resistance is the major cause of death of cancer patients with disseminated 
tumors (Borst, 2012). In some patients intrinsic (or primary) drug resistance is already observed from 
the start (i.e. prior to chemotherapy) and tumors grow in the presence of chemotherapy (Holohan et 
al., 2013). Such intrinsic drug resistance can be a cancer-type specific or caused by individual cancer 
features (Gottesman, 2002). Frequently however, resistance arises in two steps. The tumor initially 
responds, but not all tumor cells are eradicated. From the residual disease the tumor regrows and 
eventually becomes resistant to all available chemotherapeutic drugs (Borst, 2012). We have recently 
reviewed various mechanisms that may cause minimal residual disease (Blatter and Rottenberg, 
2015). Although residual disease may already contain selected drug-refractory tumor cells, it is also 
possible that the residual tumors are only transiently resistant due to cell cycle characteristics (Pajic et 
al., 2017). Then, drug resistance is acquired during the course of treatment (Housman et al., 2014). 
This secondary resistance is often due to (epi-)genetic alterations arising during the treatment and 
lead to, for instance, the activation of alternative signaling pathways, increased drug efflux, altered 
drug target availability, or rewiring of the DNA damage response (Holohan et al., 2013, Borst, 2012, 
Bouwman and Jonkers, 2012). To attenuate the development of drug resistance, combinational 
therapies of several drugs with different molecular mechanisms are frequently given to cancer 
patients (Al-Lazikani et al., 2012). Another approach is to re-sensitize resistant tumor cells by drugs 
targeting the resistance mechanism or the tumor microenvironment (De Henau et al., 2016, Callaghan 
et al., 2014). Unfortunately, we often lack knowledge about the mechanisms underlying resistance 
and therefore we usually lack a personalized strategy how to treat patients with (relapsing) tumors. 
In the past decades, progress in the treatment of disseminated cancers has reduced cancer-
related mortality (Kort et al., 2009). In addition to classical chemotherapy, also targeted anti-cancer 
drugs further improved cancer remission (Motzer et al., 2015, Zhou et al., 2011). Despite these 
advances, treatment failure due to drug resistance remains a substantial challenge in the clinical 
management of cancer. Treating a non-responsive tumor causes side effects without providing a 
benefit for the patient. Moreover, it incurs unnecessary costs and may even decrease the likelihood of 
success of subsequent treatments with other regimens (Siddiqui and Rajkumar, 2012). 
To improve cancer therapy outcome, precision oncology is a promising strategy. Through the 
assessment of a tumor’s specific genetic or proteomic changes, i.e. its biomarkers (Mehta et al., 
2010), an individualized best treatment regimen can be chosen. Prognostic gene expression 
signatures are clinically well established, because prognosis of tumor recurrence directly depends on 
the altered expression of a number of genes involved in tumor progression and metastasis (Reyal et 
al., 2008, Wirapati et al., 2008, Cardoso et al., 2016). Conversely, a tumor’s response to a particular 
treatment can fail due to the alteration of a single gene, such as the drug target or drug entry 
transporter (Borst and Wessels, 2010). Such alterations may not reliably be picked up by standard 
gene expression profiling. Thus, it is not surprising that only few predictive biomarkers are 
established, and even those remain imperfect in predicting therapy success. Currently, biomarkers 
are only available for targeted therapies, which block or stimulate specific pathways of tumor cells 
4 
 
(Twomey et al., 2017) and usually yield good initial response with a modest effect on overall survival 
(Fojo and Parkinson, 2010). In contrast, classical cytotoxic chemotherapy interferes with all rapidly 
dividing cells, does not rely on oncogenic protein or pathway alterations, but often results in long-term 
remission and even cures some cancer types, and reduces cancer-related mortality. Unfortunately, 
not all patients benefit from the treatment and many eventually become resistant to all drugs 
available. Hence, there is a lack of clinically validated predictive biomarkers for classical 
chemotherapy. 
Regarding targeted therapy, an early example of a predictive biomarker is HER2 expression 
status for trastuzumab treatment in metastatic breast cancer, an anti-cancer drug approved by the 
FDA in 1998. In combination with classical chemotherapy, trastuzumab efficiently decreases disease 
progression in HER2-amplified metastatic breast cancer (Cobleigh et al., 1999). In contrast, 
trastuzumab provides no benefit in breast cancer patients lacking HER2. Unfortunately, only about 
30% of all HER2-positive breast cancer patients respond to trastuzumab-containing chemotherapy 
(De Palma and Hanahan, 2012). Thus, there are additional factors that influence therapy response, 
such as the intertumoral heterogeneity among a cancer (sub-) type, reflecting variations in molecular 
profiles of cancers in different patients. Additionally, the intratumoral heterogeneity complicates 
predictions of drug response (Ng et al., 2014). Molecular and genetic profiling of tumors has become 
cheaper and is often readily available. For mutations in specific genes, for instance BRAF, the effect 
on therapy response has been well characterized, so that sequencing of the corresponding genomic 
region will directly yield a predictive marker for therapy response. Unfortunately, the number of such 
well-defined biomarkers is limited, and to date only a small fraction of cancer patients directly benefit 
from established biomarkers. This is aggravated by the fact that not all patients bearing BRAF 
mutations do respond equally well to targeted BRAF inhibitors (Corcoran et al., 2015, Long et al., 
2014, Prahallad et al., 2012). Thus, even such well-defined biomarkers are not sufficient, and 
additional characterization of the tumor is needed.  
Several approaches have successfully identified novel molecular peculiarities which serve as 
predictive biomarkers. Hypothesis-driven approaches have, for instance, resulted in the establishment 
of BRCA1/2 mutational status in predicting a positive response upon PARP inhibitor treatment in 
breast and ovarian cancer (Farmer et al., 2005, Tutt et al., 2010, Bryant et al., 2005). Analyses of 
large, population-based clinical trials have also identified subgroups of responsive patients (Uryniak et 
al., 2011), e.g. leukemia patients with the Philadelphia chromosome responded better to imatinib 
treatment (Druker et al., 2001). Predictive markers based on clinical data have also been suggested 
for classical chemotherapeutics, including high HER2 or low tau expression as markers for paclitaxel 
sensitivity (Pusztai, 2007). Besides BRCA1/2 status, these markers have not entered the clinic, 
however, and still require additional validating clinical studies (Schork, 2015). 
In recent years, advances in experimental genetic screening techniques have linked many 
genotypes to novel phenotypes in mammalian cells (Chen et al., 2015, Brockmann et al., 2017, Zhou 
et al., 2014b, Blomen et al., 2015, Wang et al., 2015b, Hart et al., 2015). Furthermore, genome-wide 
screens have broadened our understanding of molecular mechanisms responsible for therapy 
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response ((Ruiz et al., 2016, Berns et al., 2016, Planells-Cases et al., 2015, Wijdeven et al., 2015), for 
instance; and Table 1. Thus, these screens are valuable tools which can reveal novel mechanisms of 
resistance or hypersensitivity towards drugs, and facilitate a better understanding of drug response 
which might ultimately result in novel predictive biomarkers (Figure 1). While most targeted anti-
cancer therapeutics exploit gain-of-function alterations, e.g. in terms of oncogene addiction (Pagliarini 
et al., 2015), not all tumors bear targetable gain-of-function mutations. Inactivation of tumor 
suppressor genes is frequent, and cannot be directly targeted with a drug. However, as shown by the 
example of PARP inhibitor treatment in BRCA1/2 mutated tumors, loss of a tumor suppressor can 
offer a treatment option with low side effects for healthy tissue. The study of synthetic lethality and 
context-dependent gene essentiality has been challenging in mammalian cells and was for long time 
limited to few model organisms. With the development of CRISPR/Cas9 genome editing and 
insertional mutagenesis in haploid human cells, it is now possible to efficiently study genetic 
interactions as well as the functional consequence of genetic mutations and possibly reveal new 
predictive biomarkers by linking drug-responsive phenotypes to genotypes.  
Although some novel anti-cancer drugs have been successful and have yielded 
improvements for cancer patients, they remain imperfect (Fojo and Parkinson, 2010, Groenendijk and 
Bernards, 2014), and have also become a financial burden for the health system (Kantarjian et al., 
2013, Aggarwal, 2010, Prasad and Mailankody, 2017, Fojo and Parkinson, 2010). During the course 
of treatment, most patients sooner or later also received classical chemotherapy including platinum 
drugs, topoisomerase inhibitors, microtubule-targeting agents or antimetabolites as part of standard 
care (Gonen and Assaraf, 2012, Giovannetti et al., 2017). Their clinical use is based on empirical 
experience. However, these drugs are relatively cheap, effective and widely used. If clinical 
oncologists could be supported in their choice of classical chemotherapy based on molecular 
characteristics of a tumor, the therapeutic benefit of a standard treatment may increase and drugs to 
which the tumor is unlikely to respond would be avoided. To improve the proper selection of the 
treatment of choice and to expand our repertoire of drug response predictions, one needs to identify 
more molecular peculiarities of tumors which impact therapy response. 
This review therefore elaborates on genome-wide screening techniques in mammalian cells 
with special emphasis on the response against classical cytotoxic drugs. 
 
2. Forward genetic screens to improve our understanding of drug resistance and synthetic 
lethality. 
 Using forward genetic screens, genetic mutations can efficiently be linked to phenotypes of 
interest and identify the crucial genes for the selected phenotype. The success of a screen depends 
on the choice of the best model as well as efficient gene suppression. Genome-wide screens were 
made possible in mammalian cells with the discovery of RNA interference, which introduces small 
specific RNA molecules into cells and targets the corresponding host mRNA for degradation (Carthew 
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and Sontheimer, 2009, Brummelkamp et al., 2002). RNA interference screens have led to the 
discovery of novel predictive biomarkers for chemotherapy response which could be translated into 
the clinic. For instance, large-scale RNA interference screens identified loss of PTEN as a 
determinant of trastuzumab resistance in breast cancer (Berns et al., 2007) and feedback activation of 
EGFR as a resistance mechanism in BRAF-mutated colorectal cancer (Prahallad et al., 2012). 
However, for many applications RNA interference screens are imperfect, because this technique 
usually fails to inactivate gene function completely and remaining gene activity may mask the 
phenotype (Echeverri et al., 2006, Booker et al., 2011, Kaelin, 2012), although in some cases, such 
as the knock-down effect of essential genes on drug response, an incomplete gene inactivation might 
be required to detect an effect of the knock-down on drug response. Nevertheless, off-target effects 
complicate RNA interference screens through a high proportion of false positive hits. As RNA 
interference screens for biomarker discovery have been reviewed elsewhere (Mullenders and 
Bernards, 2009, Iorns et al., 2007, Swanton et al., 2008), we will focus here on more recent 
developments in screening technologies (Table 2 and Figure 2).  
 
2.1 CRISPR/Cas9 screens in 2D cell lines 
 The discovery of the bacterial Cas9 endonuclease has revolutionized genome engineering. A 
20-basepairs site-specific single guide RNA (sgRNA) directs the endonuclease to its corresponding 
target site and introduces a DNA break. This break stimulates repair by non-homologous end-joining 
(NHEJ) or homology-directed repair (HDR) by frequently introducing frameshifts by indel mutations, 
resulting in a premature stop codon or nonsense-mediated decay of the transcript. Consequently, 
gene inactivation is achieved at the genomic level by CRISPR (clustered regularly interspaced short 
palindromic repeats)/Cas9 by creating a gene knock-out which, for many applications, outperforms 
gene knock-down by RNA interference (Evers et al., 2016, Hart et al., 2015, Wang et al., 2015b). 
CRISPR/Cas9 also allows the study of inactivation of non-transcribed elements (Wang et al., 2014b).  
 
2.1.1 Choice of cellular model 
The universal applicability of CRISPR/Cas9 screens in a broad repertoire of models (Wang et 
al., 2015b) makes this technique a powerful tool to study cancer-type-specific genetic requirements. 
The most outstanding advantage of CRISPR/Cas9 is that genetic mutations can be introduced into 
versatile cellular models. Some mechanisms of drug resistance or hypersensitivity might only be 
present in a certain lineage or cancer type. Melanoma patients bearing the valine-to-glutamate 
change at residue 600 (V600E) of BRAF, for instance, respond well to a BRAF inhibitor in 
combination with a mitogen/extracellular signal-regulated kinase (MEK) inhibitor (Long et al., 2014), 
whereas the same treatment in colorectal patients bearing the same BRAF mutation is less efficient 
(Corcoran et al., 2015).  It may therefore be necessary to study specific genetic requirements in 
several models to identify novel genetic dependencies originating from pathway rewiring following 
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genetic perturbations. Exploiting such lineage-specific vulnerabilities could identify targets for use in 
personalized medicine (Muller et al., 2012).  
Despite this major advantage, the large genetic variation between tumor cell lines may also 
hinder the successful identification of genetic contributions to a phenotype. The efficacy of genetic 
modification of CRISPR/Cas9 depends on the number of target loci in the genome. Whereas most 
human cells are diploid, cancer cell lines often have increased numbers of chromosomes or individual 
gene amplifications due to genomic instability (Stratton et al., 2009). To inactivate genes in HeLa 
cells, for instance, which have up to five copies of a chromosome (Landry et al., 2013), Cas9 needs to 
cleave the locus with higher efficiency compared to a cell line with a diploid gene set. Screens 
performed in diploid cells will therefore likely yield more robust data with a higher signal-to-noise ratio 
compared to polyploid cells. Furthermore, cells adapt to genetic mutations with secondary genetic 
changes or other forms of compensation (Teng et al., 2013). This needs to be particularly considered 
when comparing studies in long-term cultured isogeneic cells (Housden et al., 2017). Due to the 
individual variation of genes affecting their genetic interactions, every cell line will have a different 
essentialome. Combining several screens from multiple cell lines can therefore identify the “core 
essentialome” of a lineage, while at the same time some information will be missed as a result of the 
variation in genetic context between cell lines. Hence, the properties of the chosen cell line directly 
impact screening results. 
Moreover, the activity of DNA repair pathways in a cell line influences mutation efficiency by 
CRISPR/Cas9. The introduced DNA break can be repaired by HDR, which uses a homologous DNA 
template such as a sister chromatid. HDR is usually error-free, resulting in an unchanged genomic 
locus. The success of genetic inactivation using CRISPR/Cas9 therefore depends on the error-prone 
NHEJ repair pathway. The DNA cleavage site gets trimmed before re-ligation of the two DNA ends. 
This causes insertions or deletions of base pairs, resulting in a frameshift. If both HDR and NHEJ are 
active in a chosen cell line, one can expect a lower probability for complete gene inactivation in every 
locus (Miles et al., 2016). However, in cell lines lacking a functional HDR, CRISPR/Cas9-mediated 
gene knock-out has a high success rate (Miles et al., 2016).  
 
2.1.2 Impact of the sgRNA library on screening success 
To date, three major classes of CRISPR/Cas9-mediated genomic modifiers are available. The 
most common CRISPR libraries are knock-out libraries, but gene repression (CRISPRi) and activation 
(CRISPRa) libraries are also employed for specific research questions (Lopes et al., 2016, Miles et 
al., 2016, Gilbert et al., 2014, Dominguez et al., 2016). Libraries can either be genome-wide, targeting 
for example about 20,000 genes (Sanjana et al., 2014), or specifically designed to study one 
particular pathway or a selection of genes of interest (Zhou et al., 2014b). For instance, within a 
genetic region of interest, CRISPR/Cas9 tiling screens are able to dissect which genetic segments 
encode functional domains relevant for a phenotype (Korkmaz et al., 2016). Recent developments of 
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the CRISPR system for RNA targeting or base editing will further broaden the investigable research 
fields (Cox et al., 2017, Gaudelli et al., 2017). 
The selection of the individual sgRNAs in a library directly impacts screening results. For loss-
of-function screens, sgRNAs should preferably target an early, constitutively expressed exon of a 
gene of interest. Ideally, this leads to nonfunctional transcripts of all gene variants with no off-target 
activity on other genes. Most commercially available libraries contain 5-10 sgRNAs per gene 
designed to achieve high cleavage efficacy and low off-target activity. However, these libraries do not 
take potential genomic pleomorphisms of different cell lines into account, and for some genes, shorter 
sequence variants might not be targeted and retain some gene functionality. 
Off-target effects arise from partial complementarity of the sgRNA target site with additional 
unintended target sites. Off-target effects can be reduced by the use of improved Cas9 nuclease 
variants, e.g. by a decreased binding efficacy and increased site specificity, by the use of alternative 
endonucleases or improved bioinformatics algorithms to design specific sgRNAs (Kleinstiver et al., 
2016, Slaymaker et al., 2016, Kim et al., 2016, Zetsche et al., 2015, Doench et al., 2014). This, in 
turn, increases the need for a perfect alignment of the sgRNA sequence with the target site. A single 
nucleotide mismatch as a cell line-specific genomic variation or the introduction of a terminal G during 
sgRNA design could by itself prevent sgRNA alignment with the target site. Moreover, optimized PAM 
sequence variants may also improve site specificity (Kleinstiver et al., 2015). 
Another crucial step in CRISPR/Cas9 screens is the efficacy of library transduction in a cell 
line. Typically, sgRNA libraries are transduced at a MOI of 0.4 to 0.6 to ensure that every cell contains 
only a single sgRNA (Shalem et al., 2014, Wang et al., 2014b). For successful screens, a single copy 
of each sgRNA needs to cleave both (or even more) copies of the target locus (Wang et al., 2014b). If 
more than one sgRNA is introduced into a single cell (as usually achieved through direct transfection), 
it is challenging to determine which sgRNA caused the phenotype due to the relatively low number of 
distinct sgRNAs. In contrast, less than one sgRNA per cell can lead to insufficient library coverage at 
the end of a screen. 
 Depending on the plasmid system used to deliver the library, a stable expression of both 
sgRNA as well as Cas9 increases the genomic cleavage over time (Wang et al., 2014b). This may be 
on purpose, but it might also be problematic when screens are performed over a long time period, as 
not only on-target sites but also off-target sites will be cleaved repeatedly. DNA double strand breaks 
also result in genotoxic stress, causing a non-specific anti-proliferative effect which limits the use of 
CRISPR/Cas9 for highly amplified genomic regions (Aguirre et al., 2016, Munoz et al., 2016, Housden 
et al., 2017). 
 
2.1.3 Data analysis 
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Owing to the popularity of CRISPR/Cas9 screens, a broad spectrum of resources for data 
analysis is available. To analyze a screen, sgRNA sequences are amplified by PCR before deep 
sequencing. The library sequencing reads may subsequently be analyzed using publically available 
algorithms, including HitSelect (Diaz et al., 2015) or MaGeCK (Li et al., 2014b). Although they require 
some programming experience, these algorithms are widely used, relatively user-friendly and provide 
a certain consistency in the analysis of many CRISPR/Cas9 screens. 
When analyzing CRISPR/Cas9 screens, it is crucial to remember that sgRNA copy 
abundance is counted as an indirect measurement of mutations. Not every sgRNA necessarily 
creates a frameshift mutation, since the DNA break can also be repaired error-free by HDR or with an 
in-frame mutation retaining functionality of the transcript. When a sgRNA introduces both frame-shift 
and in-frame mutations, resulting in a mixed phenotype of this sgRNA, it is possible that this sgRNA 
will not score as being significant in the analysis (Shalem et al., 2015).  
 
2.1.4 Applications to study drug response 
CRISPR/Cas9 screening technology has enabled a systematic analysis of gene function in 
mammalian cells in terms of both positive (enrichment of mutants) and negative selection (depletion 
of mutants) (Wang et al., 2014b, Shalem et al., 2014, Zhou et al., 2014b, Wang et al., 2015b). Already 
at an early stage of development of the CRISPR/Cas9 technology, it has been shown that 
multiplexing with several sgRNAs can be achieved in vitro as well as in vivo (Horii et al., 2013, Wang 
et al., 2013, Cong et al., 2013, Mali et al., 2013).  
In general, positive selection screens are less prone to alterations in library representation 
than negative selection screens which require a quantitative evaluation of sgRNA abundance. A good 
coverage and few false positives made CRISPR/Cas9 screens a valuable tool to study resistance 
phenotypes. In terms of anti-cancer drug resistance, for instance, genes were identified whose loss-
of-function-mutations cause resistance to vemurafenib, cytosine arabinoside, 6-thioguanine and DNA 
topoisomerase II (Shalem et al., 2014, Kurata et al., 2016, Koike-Yusa et al., 2014, Wang et al., 
2014b). As an example, Shalem et al., identified two known mediators of resistance against the BRAF 
inhibitor vemurafenib, NF1 and MED12 (Huang et al., 2012, Whittaker et al., 2013) in a genome-wide 
CRISPR/Cas9 library screen targeting 18,080 genes with 3-4 sgRNAs/gene (Shalem et al., 2014). 
Additionally, the authors found novel genes which had not been linked to BRAF inhibitor response so 
far, and validated their inactivation as resistance factors towards vemurafenib in vitro. Among those 
genes were members of the STAGA complex which recruit Mediator complex proteins including 
MED12, which negatively regulates TGF-β, to c-myc activating cell proliferation (Liu et al., 2008). 
Thus, CRISPR/Cas9 screens are able to identify novel mechanisms of anti-cancer drug resistance. 
For the analysis of negative selection screens, the abundance of all sgRNAs needs to be 
quantified to identify the sgRNAs that were depleted from the population. As a consequence, gene 
knock-out efficacy needs to be close to 100% because every remaining non-modified cell or in-frame 
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modification may mask the phenotype. These screens are less robust compared to positive selection 
screens and thus depend on more extensive statistical analysis, which in turn could be complicated 
by poor sgRNA-mediated cleavage efficacy. Despite these technical hurdles, CRISPR/Cas9 screens 
have successfully identified essential genes in mammalian cells (Wang et al., 2015b, Hart et al., 
2015), as well as synthetic lethal genetic interactions which could potentially serve as targets for 
cancer therapy (Toledo et al., 2015, Steinhart et al., 2017). For instance, a study focusing on synthetic 
lethal interactions with oncogenic Ras identified critical regulators of the MAPK pathway in acute 
myeloid leukemia cell lines (Wang et al., 2017). 
Moreover, CRISPR/Cas9 screens have proven useful to study intracellular phenotypes by 
employing reporter- or antibody-labelled quantitative protein measurements (DeJesus et al., 2016, 
Parnas et al., 2015). This type of screen compares cell populations with high and low signal 
measurements, and couples genes to an intracellular phenotype which does not necessarily result in 
altered cell viability. Studying such intracellular phenotypes broadens the understanding of key 
biological processes, and may identify crucial genetic dependencies of a phenotype of interest.  
 
 
2.2 Haploid insertional mutagenesis screens 
 Insertional mutagenesis screens are a powerful alternative to CRISPR/Cas9 screens. They 
provide the possibility of applying principles of classical genetics in mammalian cells to uncover 
fundamental biological processes in a highly comparative manner. In particular, recessive genetic 
screens in haploid yeast have substantially contributed to gene discovery and our understanding of 
development, basic physiology, and various diseases (Giaever and Nislow, 2014). It was therefore a 
great achievement of Thijn Brummelkamp and coworkers to establish insertional mutagenesis 
screens in haploid human cell lines and thereby increase the power of insertional mutagenesis in a 
mammalian system (Carette et al., 2009). 
 
2.2.1 Haploid cell lines  
Insertional mutagenesis screens crucially depend on haploid (or near-haploid) cell lines, 
because no second copy of the gene exists which could phenotypically mask the effect of gene 
inactivation. Thus, genetic manipulation is highly efficient in haploid cells. To date, only few haploid 
cell lines exist. The KBM7 cell line, derived from a chronic myeloid leukemia patient, is haploid except 
for chromosome 8 (Kotecki et al., 1999). Its non-hematopoietic derivate HAP1 is haploid for all 
chromosomes, except of a duplicated 30-megabase fragment of Chromosome 15 fused to 
Chromosome 19, which was excised to obtain the fully haploid eHAP cell line (Essletzbichler et al., 
2014). With the isolation of haploid human, murine, rat and monkey embryonic stem cells, a broader 
repertoire of haploid cell lines is currently being established, also by further differentiating these cells 
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into several lineages (Elling et al., 2011, Leeb and Wutz, 2011, Sagi et al., 2016, Yang et al., 2013, Li 
et al., 2014a). 
Compared to CRISPR/Cas9 screens, the restriction to a few haploid cell lines, limits the use 
of haploid screens in the study of lineage-specific biology. However, this limitation simultaneously 
provides an opportunity, exemplified by the achievements of yeast genetics where a well-
characterized single-model organism unveiled numerous insights into diverse biological processes 
(Giaever and Nislow, 2014, Boone et al., 2007). By introducing genetic alterations into a clearly 
defined, controlled genetic background, effects of gene inactivation can be studied and compared with 
precision, facilitating the investigation of complex genetic effects and interactions (Costanzo et al., 
2016, Brockmann et al., 2017). Subsequently, findings from haploid screens may be validated in a 
variety of cell lines to address lineage-specific variations. 
 
2.2.2 Insertional mutagenesis 
 In contrast to CRISPR/Cas9 screens, which depend on a sgRNA library, mutations are 
usually achieved by random mutagenesis in haploid screens. The choice of the random mutagenesis 
technique is commonly determined by the ease of retrieving genetic mutation sites for analysis from a 
pool of cells, with transposon- or retroviral gene-trapping being the most frequent mutagenesis 
strategies to date. Mutagenesis performed by gene-trapping is highly efficient and delivers a 
molecular tag to identify mutations in the genome, by integrating an exogenous viral DNA section in 
the host genome which marks the mutation site (Carette et al., 2009). The gene-trap cassette 
introduces a splice acceptor site, followed by a polyadenylation signal, which prematurely terminates 
gene splicing and translation and thereby creates mutants resembling knock-outs (Carette et al., 
2009). Transposon-mediated gene-trap mutagenesis is achieved by co-transfecting a gene-trap 
vector with a plasmid for transposase expression. The transposase stimulates insertion of the gene-
trap in the genome, and by varying transposase expression, the gene-trap insertion frequency can be 
influenced (Mates et al., 2009, Pettitt et al., 2015). 
 In theory, gene-trapping mutation events occur all over the genome and this technique 
therefore provides a very high coverage. However, the gene-trap integration is not completely 
random, as preferred viral or transposon integration sites exist (Lee et al., 2007, Wang et al., 2014b, 
Carette et al., 2009, Blomen et al., 2015). Nevertheless, a genome-wide distribution of integration 
sites, for example integrations in more than 98% of expressed genes by retroviral gene trapping 
(Carette et al., 2011a), is achieved, and improved vectors can reduce integration bias (Schnuetgen et 
al., 2008).  
Compared to the use of sgRNA libraries which employ a guiding RNA strand defining the 
target site and directly depend on sgRNA representation as well as cleavage success and error-prone 
DNA repair, insertional mutagenesis creates individual mutations at a higher frequency and efficiency 
(Blomen et al., 2015). The phenotypic effect of a gene is determined indirectly in CRISPR/Cas9 
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screens, usually by determining the abundance of DNA encoding the sgRNAs. In contrast, sensitive 
amplification of gene-trap insertion sites allows a direct count of hundreds of independent mutations in 
a gene, achieving a high resolution of the observed phenotype (Elling and Penninger, 2014). 
 However, similar to the need of a sgRNA disrupting all gene variants simultaneously to 
abolish gene function, alternative splicing as well as gene-trap integrations near the 3’ end of a gene 
can also maintain (partial) gene activity (Blomen et al., 2015). 
 
2.2.3 Data analysis 
 Deep sequencing following PCR amplification retrieves millions of unique gene-trap 
integration sites which are mapped to the genome, allowing subsequent direct counting of individual 
knock-outs that each has contributed to the phenotype of interest. The large number of individual 
mutants permits powerful statistical analyses. This enables an improved distinction between hits and 
background noise compared to other screening methods (Elling and Penninger, 2014). Due to the 
high efficacy of gene disruption and the absence of second gene copies, haploid cells further improve 
the signal to noise ratio compared to screens performed in diploid cells, enabling the identification of 
subtle fitness defects or advantages (Wang et al., 2014b, Blomen et al., 2015).   
  To analyze insertional mutagenesis screens, basic statistical tests such as Fisher's exact 
and/or binomial tests are usually employed. However, for complex research questions, such as the 
study of a cell line’s essentialome, more complex algorithms are used (Blomen et al., 2015). Recently, 
bioinformatics pipelines have been proposed for the analysis of gene-trap insertional mutagenesis 
screens (Yu and Ciaudo, 2017, Mayor-Ruiz et al., 2017). 
 
2.2.4. Applications to study drug response 
 Initially, haploid insertional mutagenesis screens were predominantly employed to study 
resistance factors of host cells towards pathogens (Carette et al., 2009, Carette et al., 2011b, 
Guimaraes et al., 2011, Jae et al., 2013). Furthermore, haploid screens yielded novel insight into 
resistance against chemical compounds including chemotherapeutic agents like platinum drugs, 
topoisomerase II, PARP, and other chemical inhibitors (Wijdeven et al., 2015, Planells-Cases et al., 
2015, Pettitt et al., 2013, Shen et al., 2016, Heijink et al., 2015). Regarding platinum drugs, it has 
been unclear which transporters are responsible for reduced drug uptake that may explain clinical 
drug resistance (Borst et al., 2008). Using a haploid screen, we identified volume-regulated anion 
channels composed of LRRC8A and D as a cellular uptake mechanism of cisplatin and carboplatin 
(Planells-Cases et al., 2015), providing a new lead to understand clinical resistance. Similarly, 
proposed resistance mechanisms against topoisomerase II inhibitors, such as doxorubicin, cannot 
explain all cases of therapy failure in the clinic (Pommier, 2013). Here, a haploid screen identified 
novel resistance mechanisms which reduce DNA double strand break formation or stimulate DNA 
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repair (Wijdeven et al., 2015). Although gene trap viruses should be inactivating, a gain-of-function 
mutation cannot be excluded. For example, we found a significant enrichment of integrations that 
induce the ABCG2 gene expression upon topotecan selection (Guyader, Blomen, Gerhards, 
Brummelkamp and Rottenberg, unpublished results). Despite the technical differences between 
haploid and CRISPR/Cas9-positive selection screens, direct comparisons of both approaches showed 
high concordance (Marceau et al., 2016, Timms et al., 2016, Wang et al., 2015b). 
 The inactivation of genes at high efficiency makes haploid screens very effective for negative 
selections, as most sense integrations in an intron will lead to reproducible and complete depletion of 
a gene (Elling and Penninger, 2014, Burckstummer et al., 2013). Since negative selection aims at 
identifying mutations that are depleted from a population of mutants, which is easily influenced by 
environmental factors, a robust identification of depleted mutations of the pool of cells can be 
challenging. A unidirectional design of the gene-trap cassette overcomes this problem and has 
facilitated the identification of essential genes in human cells as well as genotype-specific gene 
requirements by using the distribution of sense and antisense orientations as a readout for gene 
essentiality (Wang et al., 2015b, Blomen et al., 2015, Haarhuis et al., 2017). Haploid screens have 
furthermore been employed to study genotypes which sensitize cells to chemical compounds (Pettitt 
et al., 2017). For instance, we have recently found that loss of the tumor suppressor FBXW7 sensitize 
cells to Vinca alkaloids. This finding might aid the choice of microtubule-targeting chemotherapeutic 
drugs in patients (Gerhards et al., submitted). 
 Similar to CRISPR/Cas9, reporter- or antibody-based haploid screens have deciphered 
genetic modifiers of various intracellular phenotypes regardless of their effect on the viability of a cell 
(Brockmann et al., 2017, Lebensohn et al., 2016, Mezzadra et al., 2017, Timms et al., 2016, Lee et 
al., 2013). For instance, a reporter-based haploid screen for transgene silencing demonstrated the 
potential of this methodology to study epigenetic changes in human cells (Tchasovnikarova et al., 
2015). Epigenetic mechanisms such as DNA methylation or histone modifications are considered to 
drive secondary drug resistance by altering the expression of genes involved in drug transport, DNA 
repair or apoptosis (Wilting and Dannenberg, 2012, Brown et al., 2014). As genetic reporters are not 
available for all intracellular processes, antibody-based screens in fixed mutagenized cells further 
expanded the scale of query phenotypes that can be studied (Brockmann et al., 2017). Hence, 
haploid screens can contribute to our understanding of the epigenetic drivers of drug resistance and 
potentially identify novel therapeutic strategies.  
 
2.3 In vivo screens 
 Screens in 2D models are affected by assay conditions, the choice of cell lines as well as their 
growth on plastic in high oxygen. It has been shown that results vary between labs despite similar 
approaches (Scholl et al., 2009, Babij et al., 2011). Furthermore, it has been shown that tumors 
exhibit contrasting drug responses ex vivo and in vivo (Teicher et al., 1990) and that a tumor’s 
microenvironment impacts drug response (Straussman et al., 2012). Additionally, comparisons of 
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patient-derived and control cell lines revealed that the variation rather reflects the genetic background, 
culture conditions and cell line history than a disease-relevant phenotype (Soldner and Jaenisch, 
2012, Gillet et al., 2011). Thus, 2D cancer models encounter limitations regarding their clinical 
relevance and their application to study complex phenotypes such as metastasis formation or a host’s 
immune response. In vivo screens can overcome these limitations and bridge the gap to clinically 
more relevant settings. They allow not only assessing tumor cell-intrinsic contributions to drug 
sensitivity or resistance, but also take a body’s microenvironment and immune response into account. 
 
2.3.1 Choice of model 
 In vivo screens may be conducted by using a large cohort of knock-out animal models 
(van der Weyden et al., 2017). However, this approach is not feasible for all laboratories, as the 
majority does not have an extensive collection of animal models. With the development of 
CRISPR/Cas9, powerful and fast alternatives became available. CRISPR/Cas9 can be employed for 
ex vivo gene editing of cells which are subsequently transplanted into recipient mice or for non-
germline manipulation of tumors in vivo. Somatic delivery of Cas9-expressing cells can cause an 
immune response clearing those cells (Wang et al., 2015a). Therefore, Cas9-transgenic mice are 
frequently employed, which only require locally or systemic delivery of the sgRNAs, for instance 
through lentiviruses, into mice (Platt et al., 2014, Annunziato et al., 2016). Alternatively, lentiviruses 
encoding both Cas9 and sgRNAs or ex vivo CRISPR/Cas9-modified cells can be injected into 
immunodeficient or Cas9-tolerant mice for in vivo screening (Chen et al., 2015, Braun et al., 2016). A 
genome-wide screen, targeting for instance 20,000 genes with 6 sgRNAs per gene, would consist of 
120,000 sgRNAs and therefore require millions of transplanted tumor cells. This is often not feasible, 
but a genome-wide screen is usually not necessary to study the phenotype of interest in vivo. For 
most in vivo screening approaches, a focused library targeting selected biological processes is 
sufficient to address the research question. 
 
2.3.2 Applications to study drug response 
The major benefit of in vivo over in vitro screens is the contribution of the animal organism to 
the phenotype. A solid tumor in vivo is a multicellular complex that interacts with its surrounding 
tissue, differing substantially from a clonal cancer cell line in a cell culture dish. The tumor 
microenvironment and tumor-stromal interactions gained increasing importance as modulators of drug 
response. For instance, stroma-induced drug resistance has been described in several preclinical 
models for chemotherapeutic drugs such as resistance to doxorubicin, vincristine or vemurafenib 
(McMillin et al., 2013).  
Until today, most in vivo screens were performed using RNA interference editing (Gargiulo et 
al., 2013, Zhou et al., 2014a, Beronja et al., 2013, Meacham et al., 2015, Rudalska et al., 2014, 
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Schramek et al., 2014). In vivo CRISPR/Cas9 screens have been employed to assess the metastatic 
potential upon gene inactivation (Chen et al., 2015). Furthermore, novel immune modulatory factors 
which could serve as immunotherapeutic targets were identified in a CRISPR/Cas9-edited melanoma 
screen in vivo (Manguso et al., 2017). Additional biological processes for in vivo screening 
approaches include the role of tumor angiogenesis and hypoxia in drug response, and basic research 
topics such as tumor development and tissue regeneration. Screens for these complex phenotypes 
are still in the process of being optimized. 
Nevertheless, limitations of pooled in vivo screens are encountered due to the complexity of 
the library, poor efficiency of virus delivery, loss of sgRNA representation and of diversity in the 
outgrown tumor after transplantation or injection, as well as the complex interactions of tumors with 
the host body (Chen et al., 2015). Furthermore, ethical concerns of performing in vivo screens may 
rise, as they require large numbers of experimental animals. 
 
 
2.4 Screens using 3D cancer organoids 
 A promising model to recapitulate in vivo tumor behavior in an ex vivo setting is the use of 3D 
organoid cultures (Clevers, 2016). These have several advantages over 2D cell lines. Traditional cell 
lines are usually clonal, immortalized cells, genetically adapted to cell culture conditions and lacking a 
tumor’s heterogeneity as well as its complex multilayered cell organization. In a solid tumor, a drug 
may not reach all cells at equal levels due to varying vascularization. This situation is mimicked to 
some extent in a 3D culture, as drugs do not freely penetrate the viscous biomaterial in which 
organoids are embedded. In contrast, all cells in a monolayer will receive equal concentrations of an 
administered drug. Furthermore, the composition and architecture of organoids correspond to the 
tissue they are derived from. Organoids can usually be expanded easily, cryopreserved and 
biobanked and efficiently genetically manipulated (van de Wetering et al., 2015, Schwank et al., 2013, 
Drost et al., 2017).  
 
2.4.1. Choice of model 
3D organoids have been generated from the eye (Eiraku et al., 2011, Nakano et al., 2012), 
brain (Lancaster et al., 2013, Pasca et al., 2015), intestine (Sato et al., 2009, Spence et al., 2011, 
Forster et al., 2014), kidney (Takasato et al., 2014, Takasato et al., 2015), liver (Takebe et al., 2013, 
Huch et al., 2013), lung (Dye et al., 2015), inner ear (Koehler et al., 2013) and other organs. 
Organoids have furthermore been derived from cancer tissues (so-called tumoroids) (Baker et al., 
2016, van de Wetering et al., 2015, Schutte et al., 2017, Pauli et al., 2017), or were transformed into 
cancer organoids by genetic modification (Drost et al., 2015, Matano et al., 2015). 3D cultures allow 
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an organ-like architecture, facilitate interactions with the extracellular matrix and provide rudiments of 
functionality (Fatehullah et al., 2016).  
Considering that organoids consist of primary cells, the passage number influences the 
organoid’s geno- and phenotype. During culturing, some cells of the heterogeneous cell pool will be 
lost, leading to a larger discrepancy between original tumor and the organoid line. When larger 
amounts of starting material is available, e.g. from large excised patient or mouse tumors, a higher 
complexity of the heterogeneous cell pool can be maintained for longer time than with little starting 
material such as a biopsy. Additionally, organoid culturing medium is frequently supplemented with 
various factors such as Noggin or R-spondin which further select cells or alter gene expression in the 
organoid culture. Thus, organoids are less robust and less well-characterized than cell lines, but the 
heterogeneity resembles more the tumors observed in patients. 
Gene editing components to modify organoids can be delivered by adenoviruses, retroviruses 
or lentiviruses (Wang et al., 2014a, Koo et al., 2012, Duarte et al., in press). The subsequently 
achieved modifications create a polyclonal pool of cells with mixed genotypes. To efficiently select 
modified cells, reporter genes can be added to the viruses. However, the introduction of genetic 
modifications will also cause additional selective pressure so that one should evaluate to what extent 
the original tumor is still fully represented in the modified organoid culture after some passages.  
 
2.4.2 Applications to study drug response 
 3D organoid cultures are useful to study drug response of patient-derived material in 
vitro. They can be archived easily and used for high-throughput analyses of drug response linked to 
their omics profiles (van de Wetering et al., 2015). Using matched samples of a PARP-inhibitor-
sensitive and -resistant BRCA2-mutated mammary tumor, we have recently shown that more 
sophisticated functional assays to measure drug response (e.g. replication fork stability) can be 
performed in tumoroids (Ray Chaudhuri et al., 2016). How reliable the in vitro drug responses are in 
predicting the drug response in the patient from whom the tumoroids were derived remains to be 
seen. When we tested several matched PARP-inhibitor-sensitive and -resistant BRCA1-mutated 
organoids in vitro, we found examples where the resistant tumors regained drug sensitivity in vitro, 
despite the stable in vivo resistance of tumors derived from these tumoroids (Duarte et al., in press). 
This illustrates that further optimization of the in vitro conditions is required to mimic the response of 
real tumors. 
The CRISPR/Cas9 system facilitates rapid genome engineering as well as forward screening 
approaches in 3D organoids (Nie and Hashino, 2017). Given the heterogeneous nature of organoids, 
these screens are more complex, their statistical power is reduced compared to screens in well-
defined genetic backgrounds and the variation of size and shape of organoids further affect 
phenotypic selections. However, the sampling error is low due to the cellular complexity of the drawn 
test sample from the given pool of cells in the tumoroid and thus 3D screening results are expected to 
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validate in vivo. So far, a CRISPR screen in lung organoids with a miniature focused library 
discovered genes involved in ciliogenesis and barrier function in the airway epithelium (Gao et al., 
2015). The high number of cells, required to ensure an appropriate coverage, needs to be taken into 
consideration when organoid screens will be performed. These numbers of cells are usually only 
obtained after several passages which might conflict with the ambition of high similarity between the 
organoids and the original tumor. Additionally, the success of organoid screens strongly depends on 
the control of organoid size with clear pathophysiological gradients, as seen in a solid tumor, while 
preventing a too large area of central necrosis. Due to a batch-to-batch variation of the extracellular 
biomaterial, reproducibility and scalability of experiments is thus far limited. Thus, large-scale screens 
remain technically challenging in tissue-derived organoids. 
However, we found that a major advantage of tumoroids is that they can serve as a rapid 
intermediate step to introduce genetic modifications, and subsequently transplant the tumors into 
mice to test drug response in vivo (Duarte et al., in press). Using tumoroids from BRCA1-mutated 
mouse mammary tumors we introduced Trp53bp1 mutations by CRISPR/Cas9 and show that the 
tumors derived from the Trp53bp1-depleted tumoroids are resistant to PARP inhibition. Importantly, 
we also observed that tumoroids exhibit high clonal heterogeneity in vivo and give rise to tumors that 
preserve the cellular complexity of the parental organoid population (Duarte et al., in press). We 
therefore conclude that these models are suitable to study the effects of intratumoral heterogeneity in 
vivo and are useful for in vivo screening approaches to identify mechanisms of drug resistance. 
Since tumoroids are more readily cultured from patient tumors than patient-derived 2D cell 
lines (Boj et al., 2015, van de Wetering et al., 2015, Duarte et al., in press), they also provide an 
opportunity to better follow a patient’s disease development. Using genome-wide CRISPR/Cas9 
mutagenesis, the essentialome of an individual tumor may be determined to provide information about 
specific vulnerabilities of this particular tumor. The patient could subsequently receive a treatment 
accordingly, and if the tumor relapses or stops responding, a new organoid line could be obtained and 
the essentialome re-analyzed by another functional genome-wide screen. This “sensitive-to-resistant-
essentialome”-comparison approach may yield new insights into drug resistance mechanisms, directly 
received from clinical patients, and provide useful information for new vulnerabilities and treatment 
options. 
In summary, organoid screens are still in the process of optimization and technical hurdles 
need to be resolved. Nevertheless, they provide a very promising approach to study complex 
contributions to a phenotype of interest in vitro that resembles treatment responses in vivo. It is very 
likely that novel factors influencing drug response will be discovered soon in tumoroid models, and 
they will further broaden our repertoire to study cancer specimens directly derived from patients. 
 
3. Conclusions 
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In contrast to targeted anti-cancer treatment, predictive biomarkers for classical 
chemotherapy have been much more difficult to identify. This might be explained by the complex 
heterogeneity between tumors due to secondary mutations, epigenetic alterations or other 
mechanisms of drug resistance which are still poorly understood (Borst, 2012). Even in a well-
characterized genetically homogeneous tumor system, such as syngeneic transplantable tumors from 
genetically engineered mouse models, the identification of genes contributing to drug response is 
limited (Rottenberg et al., 2012). Only if a gene is altered in most of the analyzed tumors, gene 
expression analysis will detect it as a predictive candidate, whereas drug response mechanisms 
present only in a subset of tumors will be missed. Given the fact that a variety of mechanisms, either 
single- or multi-genetic in nature, influence drug response, together with various mechanisms of 
action of classical chemotherapeutics, it is not surprising that we have not been very successful to 
establish predictive biomarkers for these drugs.  
The advances in screening technologies however might provide the necessary starting point 
to develop novel hypotheses which might eventually translate into clinical predictive biomarkers. 
Forward genetic screens in mammalian cells have substantially broadened our understanding of cell 
biology, the mode of action of chemical compounds and anti-cancer drug resistance or 
hypersensitivity. These approaches offer crucial tools to discover novel tumor vulnerabilities, while at 
the same time highlighting context-specific dependencies and mechanistic complexities of cancer. A 
variety of cellular features determine drug sensitivity of a cell, and drug response varies between 
individual tumors and patients, which represents a major hurdle for clinical oncologists. Frequently, 
cancer patients do not benefit from a chosen treatment but predominantly experience the side effects, 
and better predictive biomarkers are urgently needed. Forward genetic screens allow modeling of the 
complex mutational landscape of human cancer and identifying similarities or differences between 
drug effects. For instance, studies performed on cellular platinum uptake showed that carboplatin and 
cisplatin, but not oxaliplatin, are entering cells through LRRC8A/D-containing anion channels 
(Planells-Cases et al., 2015). Thus, for patients with low LRRC8A/D expression, cisplatin and 
carboplatin might not be an effective treatment regimen. Such findings may be clinically useful and, 
thus, more screens using well-established, classical chemotherapeutic drugs may further contribute to 
improved precision oncology. 
We expect that further technical improvements of existing screening technologies and the 
comparison of screens for various drugs will aid in the development of novel treatment regimens. The 
potential use of patient-derived tumoroids for drug response screens can additionally be exploited for 
personalized medicine. Future treatment concepts will increasingly be based on specific personalized 
tumor features and thus knowledge about specific tumor vulnerabilities is essential to move the field 
forward. Since classical chemotherapeutic agents are widely available, inexpensive and well-
characterized in terms of dosage and toxicity, more effort should be made to unravel the full potential 
of these drugs and assess their benefit in clinical trials for patient subgroups characterized by 
particular genetic mutations. Furthermore, new drug combinations could be suggested when the 
impact of a genotype on drug response is better understood. 
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Given the advantages and limitations of the screening techniques, the chosen approach 
should be carefully evaluated. Screening output might depend more on experimental design than on 
the technology itself, as shown by a study comparing CRISPR/Cas9 with optimized RNAi screens 
concluding that both techniques perform equally well (Morgens et al., 2016). In general, the most 
comprehensive picture will be achieved by combining several approaches. Clinical data from patients 
remain essential to validate the findings and assess the predictive potential of identified gene-drug 
dependencies. Thus, studies would benefit from more than one approach to answer the same 
question and their combination into a therapy response map might promote the translation into 
clinically predictive markers and effective treatments with improved patient life quality and overall 
survival. 
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Figure legends 
Figure 1: Exemplary workflow to discover novel predictive biomarkers based on forward genetic 
screens. 
Figure 2: Simplified layouts of the screening technologies presented in the current review. A.: 
Screens in 2D cell lines using CRISPR/Cas9 or insertional mutagenesis to study genetic contributions 
to a phenotype of interest upon drug treatment. 2D cell lines are modified with either CRISPR/Cas9 or 
insertional mutagenesis before drug exposure. Depending on the research question of interest, the 
screen can be analyzed for enrichment (positive selection, potential drug resistance genes) or 
depletion of mutants (negative selection, potential drug hypersensitivity genes) or an intracellular 
phenotype by employing antibody- or reporter-based assays. B.: Mice bearing CRISPR/Cas9-
modified tumors can be treated with a drug of interest and efficiently analyzed to study complex 
phenotypes such as metastasis formation. C.: Patient-derived organoids can be modified with 
CRSIPR/Cas9 and used for both rapid in vivo testing of a gene panel of interest and identification of 
the tumor’s ‘essentialome’. 
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Table 1
Examples of screens performed to identify unknown factors of drug response, to suggest potential therapeutic strategies or to exploit novel screening concepts.
Selection Screening method Model Identified genes - 
proof of concept
Identified genes - novel 
findings
Proposed mechanism Remarks Reference
Trastuzumab (HER2-
targeting antibody)
shRNA screen (7,914 genes), 
positive selection
HER2-amplified breast cancer 
cell line BT474
PTEN Loss of PTEN activates PI3K/AKT 
signaling
PI3K pathway activation as predictive 
marker
(Berns et al., 
2007)
Vemurafenib (PLX4032, 
BRAF inhibitor)
Kinome shRNA screen (535 genes), 
positive selection
Colorectal cancer cell line 
WiDr
EGFR BRAF(V600E) inhibition activates EGFR 
and stimulates proliferation (feedback 
activation)
Melanoma cells express low levels of 
EGFR and are thus sensitive to BRAF 
inhibition; BRAF-mutant colon cancer 
might benefit from combination of BRAF 
and EGFR inhibitors
(Prahallad et al., 
2012)
Trastuzumab (HER2-
targeting antibody)
shRNA screen (7,914 genes), 
positive selection
HER2-amplified breast cancer 
cell lines BT474, SKBR3 and 
HCC1954
PTEN ARID1A ARID1A loss activates ANXA1 which in 
turn activates AKT and causes resistance
High ANXA1  expression suggested as 
predictive marker
(Berns et al., 
2016)
Vemurafenib (BRAF 
inhibitor)
Genome-wide CRISPR/Cas9 
(18,080 genes), positive selection 
BRAF(V600E)-mutated 
melanoma cell line A375
NF1, MED12 NF2, CUL3, TADA1, 
TADA2B
TADA1 and TADA2B (member of 
STAGA complex) recruit MED12 to c-
myc to activate proliferation; MED12 
activates TGF-βR signaling and 
MEK/ERK
(Shalem et al., 
2014)
Cytosine arabinoside 
(antimetabolite)
Genome-wide CRISPR/Cas9 
(18,080 genes), positive selection
Acute myeloid leukemia cell 
line U937
DCK SLC29A associated with nucleotide salvage 
pathway and required for the uptake and 
activation of Ara-C
(Kurata et al., 
2016)
6-thioguanine 
(antimetabolite)
Genome-wide CRISPR/Cas9 
(19,150 genes), positive selection
Male mouse ES (JM8) cells Mismatch repair 
genes (Mlh1, Msh2, 
Msh6, Pms2 )
Hprt, GM15293, 
Letmd1, Olfr815, 
Prkg1, Tmem8c
Unknown candidate genes did not validate 
in subsequent in vitro  experiments
(Koike-Yusa et 
al., 2014)
6-thioguanine 
(antimetabolite)
Genome-wide CRISPR/Cas9 (7,114 
genes), positive selection
Human near-haploid chronic 
myeloid leukemia cell line 
KBM7
Mismatch repair 
genes (MSH2, 
MSH6, MLH1, 
PMS2 )
(Wang et al., 
2014b)
Etoposide (DNA 
topoisomerase II inhibitor)
Genome-wide CRISPR/Cas9 (7,114 
genes), positive selection
Human pseudo-diploid 
leukemic HL60 and near-
haploid KBM7 cell lines
TOP2A CDK6 G1-cyclin dependent kinase involved in 
etoposide cytotoxicity
(Wang et al., 
2014b)
ATR inhibitor Genome-wide CRISPR/Cas9 
(19,150 genes), positive selection
Mouse ES cells (KH2) CDC25A CDC25A prevents cells from premature 
entry into mitosis
CDC25A  levels could serve as criterion 
for patients more likely to respond; 
rationale to combine ATR and WEE1 
inhibitor treatment
(Ruiz et al., 
2016)
Phenotypic selection Genome-wide (18,543 human and 
18,986 mouse genes) and focused 
(132 Ras-associated genes) 
CRISPR/Cas9 library, negative 
selection
12 acute myeloid leukemia cell 
lines and NRAS-engineered 
mouse CGN Ba/F3 cell line
Several genes involved 
in Ras maturation or 
downstream of MAPK 
signaling pathway
Cancers driven by oncogenic Ras require 
Rac/PAK signaling to activate MAPK 
signaling
PAK inhibition as potential synthetic 
lethal therapeutic strategy in Ras-driven 
cancers
(Wang et al., 
2017)
Phenotypic selection Genome-wide CRISPR/Cas9 
(18,080 genes), negative selection
Glioblastoma stem-like and 
neural stem/progenitor cell 
lines
PKMYT1 PKMYT1 essential to inhibit cyclin B-
CDK1 activity is lost in glioblastoma
PKMYT1 inhibition as potential synthetic 
lethal therapeutic strategy in glioblastoma
(Toledo et al., 
2015)
Phenotypic selection Genome-wide CRISPR/Cas9 screen 
( 17,232 genes), negative selection
RNF43-mutant pancreatic 
ductal adenocarcinoma cell 
line
components of Wnt 
pathway
FZD5 FZD5 encodes the main receptor for Wnt-
β-catenin signaling in this context
FDZ5 inhibiton as a potential synthetic 
lethal therapeutic strategy in RNF43-
mutated pancreatic cancer
(Steinhart et al., 
2017)
Phenotypic selection Genome-wide (18,360 genes)  and 
mini-pool (300 genes) CRISPR/Cas9 
screen, quantitiative protein 
measurement of SQSTM1 
modulators
Human neuroglioma H4 cell 
line
MTOR complex 1 
and canonical 
macroautophagy 
components
ufmylation components Ufmylation induces SQSTM1 expression (DeJesus et al., 
2016)
Lipopolysaccharide Genome-wide CRISPR/Cas9 screen 
(21,786 genes), quantitative 
measurement of Tnf expression
Mouse bone-marrow derived 
dendritic cells
Tlr4, Myd88  (signal 
high), Zfp36  (signal 
low)
components of OST 
complex,  ER 
translocation pathway, 
PAF complex
(Parnas et al., 
2015)
Doxorubicin (DNA 
topoisomerase II inhibitor)
Viral gene-trap haploid screen, 
positive selection
Human haploid cell line HAP1 ABCB1, Keap1 SWI/SNF subunits, 
C9orf82, Eif4a1
SWI/SNF regulates Topoisomerase II 
activity, C9orf82 negatively regulates 
DNA repair 
Patients with low SWI/SNF expression 
should not be treated with doxorubicin but 
rather aclarubicin or topotecan
(Wijdeven et al., 
2015)
Carboplatin (platinum 
drugs)
Viral gene-trap haploid screen, 
positive selection
Human near-haploid  chronic 
myeloid leukemia cell line 
KBM7 
Components of volume-
regulated anion channel 
(LRRC8D/LRRC8A )
50% of cellular platinum drug uptake 
mediated via LRRC8A/D channels
Downregulation of LRRC8 subunits could 
have an impact on platinum resistance
(Planells-Cases et 
al., 2015)
6-thioguanine 
(antimetabolite)
piggyBac transposon haploid screen, 
positive selection
Mouse haploid ES cells Proof of concept: 
DNA mismatch 
repair pathway 
genes (Msh2, Msh6, 
Mlh1 )
Validation of loss-of-function screen (Pettitt et al., 
2013)
Olaparib (PARP inhibitor) piggyBac transposon haploid screen, 
positive selection
Mouse haploid ES cells Parp1 Parp1 is a drug target and required for 
drug toxicity
Inhibited PAPR1 enzyme forms a toxic 
DNA lesion
(Pettitt et al., 
2013)
6-thioguanine 
(antimetabolite)
Viral gene-trap haploid screen, 
positive selection
Human near-haploid chronic 
myeloid leukemia cell line 
KBM7
HPRT Enzyme converting 6-thioguanine to a 
toxic metabolite
(Carette et al., 
2009)
Imatinib (tyrosine-kinase 
inhibitor)
Viral gene-trap haploid screen, 
positive selection
Human near-haploid chronic 
myeloid leukemia cell line 
KBM7
NF1, PTPN1 PTPN12 Tyrosine phosphatase negatively regulates 
c-abl
(Carette et al., 
2009)
Formaldehyde Viral gene-trap haploid screen, 
positive selection
Human near-haploid chronic 
myeloid leukemia cell line 
KBM7
12 candidate genes 6 out of 12 candidates validated (Shen et al., 
2016)
Imatinib (tyrosine-kinase 
inhibitor)
Viral gene-trap haploid screen, 
positive selection
Human near-haploid chronic 
myeloid leukemia cell line 
KBM7
CASP10, CUX1, NF1, 
LYRM9, ZPBP, 
CEBPG
Only LYRM9  validated; only NF1  was 
also identified by Carette et al., 2009
(Shen et al., 
2016)
MK-1775 (Wee1 inhibitor) Viral gene-trap haploid screen, 
positive selection
Human near-haploid chronic 
myeloid leukemia cell line 
KBM7
SKP2,CUL1, CDK2 
(among others)
Inactivation of S-phase can overcome 
Wee1 inhibitor resistance
Activity of DNA replication machinery 
could serve as selection criterion for 
Wee1 inhibitor treatment
(Heijink et al., 
2015)
Talazoparib (PARP 
inhibitor)
piggyBac transposon haploid screen, 
negative selection
Brca2-mutated mouse haploid 
ES cells (H129.2)
Ewsr1 (Pettitt et al., 
2017)
Phenotypic selection Viral gene-trap haploid screen, 
quantitative protein measurement of 
AKT signaling 
Human haploid cell line HAP1 KCTD5; GNB1  and 
other genes encoding 
Gβγ subunits
KCTD5 negatively regulates GPCR 
signaling by triggering proteolysis of 
dissociated  Gβγ subunits
(Brockmann et 
al., 2017)
Phenotypic selection Viral gene-trap haploid screen, 
quantitative protein measurement of 
WNT signaling
Human haploid cell line HAP1 
with 7TG-WNT reporter
several known 
regulators
genes linked to WNT 
receptor complex, 
CTNNB1 destruction 
complex and others
Other processes than CTNNB1 protein 
levels , e.g. truncation of domains, might 
regulate WNT signaling
(Lebensohn et al., 
2016)
Interferon-γ Viral gene-trap haploid screen, 
quantitative protein measurement of 
PD-L1 abundance
Human haploid cell line HAP1 IFNγR-pathway, 
IRF1, CD274
CMTM6 CMTM6/4 enhances PD-L1-mediated T-
cell inhibition, stabilizes PD-L1 protein 
level
Novel potential target for immune-
suppressive cancer therapy
(Mezzadra et al., 
2017)
Phenotypic selection Comparison of genome-wide 
CRISPR/Cas9 (19,050 genes) and 
viral gene-trap haploid screen, 
quantitative protein measurement of 
ER-associated degradation of MHC 
class I molecules
Human near-haploid chronic 
myeloid leukemia cell line 
KBM7 with MHC-I-ERAD 
reporter
TXNDC11 TXNDC11 encodes an EDEM2/3-
associated disulphide reductase
(Timms et al., 
2016)
Phenotypic selection Genome-wide CRISPR/Cas9 screen 
(20,611 genes) , positive selection
mouse non-small-cell lung 
cancer cell line transplanted 
into immunocompromised 
mice
several candidate genes 
enriched in late primary 
tumors, high overlap of 
candidate genes in 
metastases
Enrichment of mutations in anti-apoptotic 
or other tumor suppressive pathways
(Chen et al., 
2015)
Monoclonal PD-1 antibody Focused CRISPR/Cas9 screen 
(2,368 genes), positive selection  
Mouse B16 melanoma cell 
line
CD47 Ptpn2 , and several 
genes involved in four 
distinct biological 
processes 
loss of Ptpn2 sensitize tumors to 
immunotherapy through increased antigen 
presentation and T-cell stimulation
Inhibition of Ptpn2 as a therapeutic 
strategy to increase the effect of anti-PD-1 
immunotherapy
(Manguso et al., 
2017)
Phenotypic selection Mini CRISPR/Cas9 screen (10 
genes), positive selection
3D mucociliary epithelial 
organoids from primary 
human basal cells
GRHL2 GRHL2 plays a key role in apical-basal 
cell polarity and epithelial morphogenesis
(Gao et al., 2015)
Table 2
Comparison of recent functional screening technologies.
Advantages Disadvantages
• Variety of cell lines or models can be used • Cell line-specific genetic pleomorphisms, adaptations or genetic 
alterations might impair screening results 
• Easy to study cancer-type- of cell lineage-specific genetic 
determinants
• Activity of DNA repair in the model impacts CRISPR/Cas9 
cleavage success
• Several distinct libraries and systems for various purposes • Dependence on representative library with efficient sgRNAs
• Ongoing developments of novel CRISPR systems for various 
applications
• Off-targets effects on unintendend genomic sites
• Publically available data analysis algorithms • In-frame mutations can mask the phenotypes
• Some consistency in data analysis between different laboratories • sgRNA abundance as indirect measurement of mutations
Advantages Disadvantages
• Application of principles of yeast genetics in mammalian cells • Limitation to few haploid cell lines, more challenging to study 
lineage-specific biology
• Every genetic region with good coverage can be studied • Integration bias of transposons or viruses
• Individual genomic mutations are directly measured • Few publically available data analysis algorithms
• High statistical power • Alternative splicing can maintain a functional transcript
Advantages Disadvantages
• Contribution of the host's microenvironment, tumor-stromal 
interactions and immune response to the phenotype of interest
• Large number of animals needed for complex libraries
• Closer to the situation in patients • Diversity of outgrown tumors
• Study of complex phenotypes such as metastasis formation or 
angiogenesis
• Interaction with microenvironment can mask effects of genetic 
manipulation
• Virus delivery or tumor outgrowth rate increases experimental 
variation
• Ethical concerns
Advantages Disadvantages
• Multilayered complex 3D organization • Loss of similarities with original tumor over time
• Resemble the original in vivo  organ • Growth factors supplemented in medium alter gene expression 
of organoids
• Heterogeneity resembles patients • Genetically less robust, poorly characterized
• Patient-derived material can be studied easily • Low statistical power
CRISPR/Cas9 in 2D cell lines
Haploid insertional mutagenesis
in vivo  screens
3D cancer organoids
